Introduction: Thalassemia is one of the most common genetic disorder of hemoglobin synthesis in Jammu region. Although RBC transfusion is life saving for these patients, it may be associated with some complications like RBC alloimmunization. Thus, the aim of this study was to determine the frequency of alloimmunization and the most common alloantibodies involved. Material and Methods: This was a descriptive study involving a total of 70 thalassemic patients in the age range of 2-17 years receiving regular blood transfusions, registered at SMGS Blood Bank, Jammu. Relevant clinical and laboratory data was collected with reference to age at the start of transfusions, total number of transfusions received and splenectomy status. Antibodies screening, antibody identification, and cross matching was done on allpatient samples included in the study, during the period between November 2009 and October 2010. Results: In this study, a total of six alloantibodies six patients (8.5%) and one autoantibody (1.42%) was detected. All identified alloantibodies belonged to Rh system (i.e. anti-E, in 3 patients (50%), anti D, in one patient (16.66%)) and Kell system (anti-K, in two patients (33.34%)). Higher frequency of alloimmunization was found, with increase in number of transfusions and in those who received transfusions after 1 year of age. Alloimmunization was not significantly associated with gender and splenectomy status (P-value > 0.05). Conclusion: Red cell alloantibodies developed in 8.5% of thalassemic patients and 1.42% had autoantibodies. The most common alloantibodies identified were anti Rh system antibodies (anti-E and anti-D) present in 50% and 16.66% of patients respectively. Alloimmunization is not an uncommon problem faced by blood banks and finding compatible units for regularly transfused thalassemic patients may become very difficult. In order to reduce alloimmunization, a policy for performing extended red cell phenotyping of these patients is essential and at least antigen E and Kell negative blood should be provided for transfusion to these patients.
Introduction Introduction
Thalassemia is a heterogeneous group of genetic disorders of hemoglobin synthesis of globin chains. In India, it is estimated that nearly 8000-10000 new thalassemics (homozygous) are born every year and beta thalassemia gene is found more commonly in Punjabis, Sindhis, Bengalis, and Gujratis. [1] The conventional treatment of beta thalassemia major is based on regular blood transfusions from early childhood. Although blood transfusion is life saving for thalassemia patients, it may be associated with some complications such as iron overload, platelet, and RBC alloimmunization. [2] Therefore, screening for unexpected antibodies should be a part of all pretransfusion testing, with antibody identifi cation in the event of a positive result. [3] Thalassemia patients enrolled for regular transfusions in our hospital belong mainly to Jammu region that lies in the thalassemic zone. This study was therefore designed to fi nd out the frequency of alloimmunization, most common alloantibodies involved to red cell antigens and the factors that might contribute to their development, so that present transfusion policies can be reviewed.
Material and Methods Material and Methods
This study was conducted over a period of one year from November 2009 to October 2010 in Department of Immunohematology and Blood Transfusion Medicine, GMC, Jammu. The study was approved by Hospital ethics committee. Written consent was taken from each patient.
Patients Patients A total of 70 thalassemia patients in the age ranging from of 2-17 years receiving multiple blood transfusions at interval of 2-4 weeks, or those who had received at least 10 transfusions, were included in this study.
Clinical transfusion records were analyzed for the presence of alloimmunization/autoimmunization with antibody specifi city, age at start of transfusion, number of blood units received, and status of splenectomy. As per transfusion strategy of our institute, all thalassemia patientswere given ABO and RhD-matched packed red cells after compatibility testing by gel card technique in the AHG phase (type and crossmatch policy).
Investigations Investigations
Using standard blood bank methods, plasma was separated and analyzed to detect antibodies to RBC antigens. Prior to every transfusion, plasma was tested for the presence of alloantibodies using commercial three cell panel, Diamed-Diacell I, II, III with homozygous expression of the antigens. Any pretransfusion sample with positive antibody screen was subjected to antibody identifi cation. The antibody identifi cation test was performed by acommercial Diamed-Diapanel 1 to 11, with known antigens against the patient's sample. The tests were done using the gel card method by Diamed ID (Switzerland), as per manufacturer's guidelines. A polyspecifi c direct antiglobulin test was performed using 0.8% cell suspension of the patient's RBC with antihuman globulin. Elution and adsorption methods were employed in patients with suspected autoantibodies.
Statistical Analysis Statistical Analysis
Descriptive statistics and fi shers exact test was used to calculate P-value, wherever necessary.
Results Results
During the study period, a total of 70 thalassemia patients were reviewed. Fifty-nine (84.28%) patients were of thalassemia major, eight (11.42%) were of thalassemia intermedia and three (4.28%) were of thalassemia minor. Though thalassemia minor patients rarely require blood transfusions but in this study, out of three patients two had chronic kidney disease due to which these children often presented with symptomatic anemia (Hb 5 g/dl) and were given transfusions. Third child had moderate to severe anemia of unknown etiology due to which this patient more often presented with symptomatic anemia, thus requiring blood transfusions. Her Lab workup fi ndings were as follows: Hb -6.5 g/dl; bone marrow picture showed hyperplasia; PBF -normocytic normochromic picture, reticulocyte counts on higher side.
Male to female ratio in this study was 1.91. The mean (standard deviation) age of patients was 9.27 (4.58) years with age ranged from 2-17 years. Eighteen patients (25.71%) were of blood group A, twenty fi ve (35.71%) were of blood group B, eight (11.44%) were of blood group AB, and nineteen (27.14%) had O blood group . The mean (standard deviation) age at start of transfusion was 1.96 years (2.25) with interquartile range of 5.35-20.83.
In this study, red cell alloimmunization was found in 6 of 70 patients (8.5%), [ Table 1 ] and only one patient (1.42%) developed autoantibodies.
The patients with alloimmunization were in the age range of 7-17 years. Mean age (standard deviation) of patients was 12.83 (4.35) years, 3 patients were <10 years old and 3 (50%) were >10 years old. Male to female ratio was 1:1. Relation between gender and alloimmunization was not statistically significant (P value = 0.33). Mean (S.D) age at fi rst blood transfusion in patients with alloimmunization was 4.7 (3.8) years, with age range from 0.6-10 years. A signifi cant association between alloimmunization and age at start of transfusion was seen. As those patients who started their transfusion at <1 year of age, only 1 out of 33 (3.03%) developed alloantibodies where as those who started their transfusion at >1 year of age, 5 out of 37 (13.57%) developed alloantibodies [ Figure 1 ].
As perrecords retrieved from thalassemic patients, the total number of transfusions received by alloimmunized patients was in the range of 71-180, with mean (S.D) of 132 (38.44). The alloimmunization rate was seen higher in those who received >12 transfusions (8.82%) as compared to those who received up to 12 transfusions, (0%). By applying Fischer exact test, P value of 0.01 was calculated which is statistically signifi cant.
In this study, out of six alloimmunized patients, splenectomy was observed in one female patient (16.6%), but she was alloimmunized before splenectomy. No significant association was observed (P value of 0.16). Discussion Discussion
The frequency of alloimmunization reported by different studies ranged from 5-30% in transfusion dependent thalassemia patients. [4] [5] [6] However, in this study, the frequency of alloimmunization was 8.5% with C.I of 0.44 to 11.56 and autoimmunization was 1.42%. This study was consistent with study by Ho et al. where frequency of alloimmunization was 7.4%. [7] Haslina et al. in 2006 reported frequency of 8.6% among Malaysian multitransfused thalassemics. [8] Similar study reported from Northern India by Pahuja et al. reported very low alloimmunization rate of 3.79%. [9] However, a study by Ahmed et al. in 2010 reported the alloimmunization rate of 11.3% in Egyptian thalassemic patients. [10] The most common alloantibody detected was anti-Rh system antibodies (anti-E seen in three patients (50%) and anti-D seen in one patient (16.66%)) followed by anti-K seen in two patients (33.34%). All of our patients received compatible blood for ABO and Rh (D) antigens after major cross matching. Several studies, have shown anti-E as most common alloantibody as reported by Sirchia et al. [3] Ho et al. detected anti-E with a rate of 21%. [10] Ameen et al. detected anti-E with a rate of 46.5%. [7] Haslina et al. detected anti-E with a rate of 44.4%. [8] One [8, 11] This study shows no significant association between alloimmunization and gender (P-value = 0.33), as male to female ratio in alloimmunized patients was 1: [13] Haslina et al. reported no signifi cant association between gender and alloimmunization (P = 0.16). [8] In this study, mean age at start of transfusion of alloimmunized patients was 4.7 years. The rate ofalloimmunization who started transfusion at <1 year of age was 3.03% compared to those who started at >1 year of age was 13.53% [ Figure 1] . Merianou et al. 1987 found that the rate of alloimmunization was signifi cantly lower when age of starting transfusion was <1 year (9% vs 38.7%). [5] Similar study by Sirchia et al. reported that those receiving transfusion before age of 6 years were less prone to antibody formation (1.1% vs 5.7%; P < 0.01). [3] These results support the view that there is some form of immune tolerance induced by animmature immune response to repeated blood transfusions. Spanos et al. reported alloantibody formation was signifi cantly less in patients where blood transfusion was started prior to age three (20.9%) as compared to when transfusion was started later (47.5%). This resistance to alloimmunization is perhaps the consequence of the immaturity of the immunological system and particularly that of antibody production. [6] In this study, we found the earliest development of antibodies was after transfusion of 12 units of packed red cells . A signifi cant association between alloimmunization and number of transfusions was observed. (P value < 0.05%). Spanos et al. reported earliest sensitization after approximately 10 transfusions in thalassemics patients. [6] In this study, 2.85% patients underwent splenectomy, only one of them had alloantibody before splenectomy (P value = 0.16). In a study in Hong Kong by Ho et al. splenectomy did not affect the incidence of alloimmunization. [7] Conclusion Conclusion Due to high incidence of anti Rh system (66.66%) and anti-K (33.3%) antibodies in our study population, it is advisable to phenotype patients and donors and matched red cell units for at least Rh blood group system and Kell blood group system antigens in addition to ABO and D antigen should be providedt. Antigenmatched transfusions should effectively prevent alloimmunization for thalassemia patients who have a lifelong, transfusion-dependent disease.
